# Dainippon Sumitomo Pharma

> Dainippon Sumitomo Pharma is a VC fund backing Health Care and Biotechnology. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Osaka, Japan
- Total investments: 6
- Last investment: Oct 2021
- Lead investor: 17%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/dainippon-sumitomo-pharma
- Website: http://www.ds-pharma.com/
- Facebook: https://www.facebook.com/pages/Sumitomo-Dainippon-Pharma/148047335210010?fref=ts

Dainippon Sumitomo Pharma is a VC fund in Osaka focused on Health Care and Biotechnology. "Green Prism", the symbol of Dainippon Sumitomo Pharma Co., Ltd. is a motif in the design of the "Sun"-expressing a lively sense of energy, moving on toward tomorrow; "Light"-to convey the potential and hope of the future; and "Flower"-engendering the joyous and liberated sensation of basking in good health.A design crafted to embody preeminent research and development powers, a thorough support system, the spirit of challenge, and the other stances of Dainippon Sumitomo Pharma-a company bent on supplying all people with the strength to push on toward an even brighter tomorrow.Emanating from the symbol, furthermore, is the image of a network, steadily spreading out into the world.

## Contacts

5 contacts available for Dainippon Sumitomo Pharma. Shizune tracks 8 team members at Dainippon Sumitomo Pharma. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/dainippon-sumitomo?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 83% |
| Biotechnology | 3 | 50% |
| Medical | 2 | 33% |
| Medical Device | 2 | 33% |
| Pharmaceutical | 2 | 33% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 2 | 33% |
| Series A | 1 | 17% |
| Post-IPO Debt | 1 | 17% |
| Debt Financing | 1 | 17% |
| Post-IPO Equity | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Japan | 3 | 50% |
| United States | 2 | 33% |
| United Kingdom | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Antony Loebel | Executive Officer & Head of Global Clinical Development | 0 | — |
| Hiroshi Noguchi | Senior Executive Vice President Drug Research; Drug Development | 0 | — |
| Hiroshi Nomura | EVP External Affairs; Corporate Secretariat & Industry Affairs | 0 | — |
| Hitoshi Odagiri | Senior Executive Officer & Executive Director, Sales & Marketing | 0 | — |
| Masaru Ishidahara | Senior Executive Officer Corporate Governance; Personnel | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Roivant Sciences | Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates.Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by building Vants - nimble, entrepreneurial biotech andhealthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying the technology. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines. | $200M | Post-IPO Equity | Oct 01, 2021 |  |
| Myovant Sciences | Myovant Sciences is to deliver innovative women's health and prostate cancer solutions by efficiently advancing new medicines to market. | $200M | Post-IPO Debt | Aug 05, 2020 |  |
| Drawbridge Health | Founded in 2015 by GE Ventures and GE Healthcare, Drawbridge Health is a privately held healthcare technology company that is focused on reinventing the blood sampling paradigm, enabling comfortable and convenient blood sample collection anytime and anywhere. Drawbridge has both internally generated IP and the exclusive license to GE’s substantialblood stabilization chemistry IP portfolio. |  | Debt Financing | Jul 24, 2019 |  |
| AlphaNavi Pharma | AlphaNavi Pharma specializes in the research and development of new drugs. | $127.6M | Series A | Apr 05, 2019 |  |
| Healios | Healios aims to commercialize the world’s first pharmaceutical hiPSC derived RPE cell transplantation for treatment of AMD in collaboration with RIKEN, one of the leading research institutes in Japan. The goal of this therapy is to promote the regeneration of retinal function and, consequently, to improve visual function in those affected withretinal degenerative diseases.The significance of the total raised capital fortifies the company’s momentum in the development of therapeutics utilizing the Nobel Prize-winning hiPSC technology and attests its uncompromising commitment to making groundbreaking strides in the field of regenerative medicine. | $425.2M |  | Oct 08, 2013 |  |
| FunPep | FunPep is an Industry-university collaboration bioventure company. |  |  |  |  |

6 of 6 investments shown.

## Co-investors
- Patient Square Capital — VC Fund, 2 deals together
- Bio-sight Capital — VC Fund, 1 deal together
- [Chuo Shinkin Venture Capital](https://shizune.co/investors/profile/chushin-venture-capital) — VC Fund, 1 deal together
- [Chushin Venture Capital](https://shizune.co/investors/profile/chushin-venture-capital-6384) — VC Fund, 1 deal together
- [Dogan](https://shizune.co/investors/profile/dogan-ac72) — VC Fund, 1 deal together
- [Eventide](https://shizune.co/investors/profile/eventide-asset-management) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Dainippon Sumitomo Pharma invest in?

Dainippon Sumitomo Pharma invests primarily in Health Care, Biotechnology and Medical startups, most often at Funding Round and Series A stage. Most of the 6 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Dainippon Sumitomo Pharma?

Public channels for Dainippon Sumitomo Pharma include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Dainippon Sumitomo Pharma?

The team at Dainippon Sumitomo Pharma includes Antony Loebel (Executive Officer & Head of Global Clinical Development), Hiroshi Noguchi (Senior Executive Vice President Drug Research; Drug Development) and Hiroshi Nomura (EVP External Affairs; Corporate Secretariat & Industry Affairs), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co